Abstract
The recent FDA approval of the first CAR immunotherapy marks a watershed moment in the advancement toward a cure for cancer. CD19 CAR treatment for B cell acute lymphocytic leukemia has achieved unprecedented remission rates. However, despite success in treating previously relapsed and refractory patients, CD19 CAR faces similar challenges as traditional chemotherapy, in that malignancy can adapt and overcome treatment. The emergence of both antigen positive and negative blasts after CAR treatment represents a need to bolster current CAR approaches. Here, we report on the anti-tumor activity of a CAR T cell possessing 2 discrete scFv domains against the leukemic antigens CD19 and CD123. We determined that the resulting compound CAR (cCAR) T cell possesses consistent, potent, and directed cytotoxicity against each target antigen population both in vitro and in vivo. Our findings indicate that targeting CD19 and CD123 on B-ALL cells may be an effective strategy for augmenting the response against leukemic blasts and reducing rates of relapse.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cobaleda, C., & Sánchez-García, I. (2009). B-cell acute lymphoblastic leukaemia: Towards understanding its cellular origin. BioEssays., 31(6), 600–609.
Typical Treatment of Acute Lymphocytic Leukemia: American Cancer Society; 2016 [Available from: https://www.cancer.org/cancer/acute-lymphocytic-leukemia/treating/typical-treatment.html.
Gaynon, P. S., Angiolillo, A. L., Carroll, W. L., Nachman, J. B., Trigg, M. E., Sather, H. N., et al. (2010). Long term results of the Children’s Cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: a Children’s oncology group report. Leukemia., 24(2), 285–297.
Oriol, A., Vives, S., Hernández-Rivas, J.-M., Tormo, M., Heras, I., Rivas, C., Bethencourt, C., Moscardó, F., Bueno, J., Grande, C., del Potro, E., Guardia, R., Brunet, S., Bergua, J., Bernal, T., Moreno, M. J., Calvo, C., Bastida, P., Feliu, E., Ribera, J. M., & Programa Español de Tratamiento en Hematologia Group. (2010). Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group. Haematologica., 95(4), 589–596.
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine, 371(16), 1507–1517.
Ruella, M., & Kenderian, S. S. (2017). Next-generation chimeric antigen receptor T cell therapy: going off the shelf. BioDrugs., 31(6), 473–481.
Gardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., Hoglund, V., Lindgren, C., Oron, A. P., Li, D., Riddell, S. R., Park, J. R., & Jensen, M. C. (2017). Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood., 129(25), 3322–3331.
Ruella, M., & Maus, M. V. (2016). Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Computational and Structural Biotechnology Journal, 14, 357–362.
Hassanein, N. M., Alcancia, F., Perkinson, K. R., Buckley, P. J., & Lagoo, A. S. (2009). Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors (“hematogones”) and B lymphoblastic leukemia blasts. American Journal of Clinical Pathology, 132(4), 573–580.
Testa, U., Pelosi, E., & Frankel, A. (2014). CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomarker Research, 2(1), 4.
Ruella, M., Barrett, D. M., Kenderian, S. S., Shestova, O., Hofmann, T. J., Perazzelli, J., Klichinsky, M., Aikawa, V., Nazimuddin, F., Kozlowski, M., Scholler, J., Lacey, S. F., Melenhorst, J. J., Morrissette, J. J., Christian, D. A., Hunter, C. A., Kalos, M., Porter, D. L., June, C. H., Grupp, S. A., & Gill, S. (2016). Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. The Journal of Clinical Investigation, 126(10), 3814–3826.
Pinz, K., Liu, H., Golightly, M., Jares, A., Lan, F., Zieve, G., et al. (2015). Preclinical targeting of human T cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Leukemia.
Chen, K. H., Wada, M., Pinz, K. G., Liu, H., Shuai, X., Chen, X., Yan, L. E., Petrov, J. C., Salman, H., Senzel, L., Leung, E. L. H., Jiang, X., & Ma, Y. (2018). A compound chimeric antigen receptor strategy for targeting multiple myeloma. Leukemia., 32(2), 402–412. https://doi.org/10.1038/leu.2017.302.
Jacoby, E., Nguyen, S. M., Fountaine, T. J., Welp, K., Gryder, B., Qin, H., et al. (2016). CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nature Communications, 7, 12320.
Zoghbi, A., zur Stadt, U., Winkler, B., Müller, I., & Escherich, G. (2017). Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement. Pediatric Blood & Cancer, e26594.
Naddafi, F., & Davami, F. (2015). Anti-CD19 monoclonal antibodies: a new approach to lymphoma therapy. International Journal of Molecular and Cellular Medicine, 4(3), 143–151.
Mamonkin, M., da Silva, D. G., Mukherjee, M., Sharma, S., Srinivasan, M., Orange, J. S., et al. (2016). Tonic 4-1BB signaling from chimeric antigen receptors (CARs) impairs expansion of T cells due to Fas-mediated apoptosis. The Journal of Immunology, 196(1 Supplement), 143.7.
Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016). T cells expressing CD19/CD20 bi-specific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunology Research., 4(6), 498–508.
Tasian, S. K., Kenderian, S. S., Shen, F., Ruella, M., Shestova, O., Kozlowski, M., Li, Y., Schrank-Hacker, A., Morrissette, J. J. D., Carroll, M., June, C. H., Grupp, S. A., & Gill, S. (2017). Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood., 129(17), 2395–2407.
Beldjord, K., Chevret, S., Asnafi, V., Huguet, F., Boulland, M. L., Leguay, T., et al. (2014). Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood., 123(24), 3739–3749.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of Interest
KGP, MW and YM are co-inventors of this technology and hold the patents related to the contents of this manuscript. YM is founder and Chairman of iCell Gene Therapeutics.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(PDF 16694 kb)
Rights and permissions
About this article
Cite this article
Yan, L.E., Zhang, H., Wada, M. et al. Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy. Stem Cell Rev and Rep 16, 385–396 (2020). https://doi.org/10.1007/s12015-019-09948-6
Published:
Issue date:
DOI: https://doi.org/10.1007/s12015-019-09948-6